進行性固形腫瘍の参加者におけるGS-0201の単独および併用の研究
進行性固形腫瘍を有する成人を対象としたGS-0201の単独療法および併用療法としての安全性と忍容性を評価する第1相試験
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors.
The primary objectives of this study are to:
- To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors
- To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Gilead Clinical Study Information Center
- 電話番号:1-833-445-3230 (GILEAD-0)
- メール:GileadClinicalTrials@gilead.com
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02459
- 募集
- Dana-Farber Cancer Institute
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
Austin、Texas、アメリカ、78758
- 募集
- NEXT Austin
-
Houston、Texas、アメリカ、77030
- 募集
- The University of Texas MD Anderson Cancer Center
-
Irving、Texas、アメリカ、75039
- 募集
- NEXT Dallas
-
-
-
-
-
Haifa、イスラエル、31096
- 募集
- Rambam Health Care Campus
-
Jerusalem、イスラエル、9112001
- 募集
- Hadassah Medical Center
-
Tel Aviv、イスラエル、6423906
- 募集
- Tel Aviv Sourasky Medical Center
-
Tel HaShomer、イスラエル、52621
- 募集
- Chaim Sheba Medical Center
-
-
-
-
-
Gangnam-Gu、韓国、06351
- 募集
- Samsung Medical Center
-
Goyang-si Gyeonggi-do、韓国、10408
- 募集
- National Cancer Center - Korea
-
Seoul、韓国、05505
- 募集
- Asan Medical Center
-
Seoul、韓国、03722
- 募集
- Yonsei University Severance Hospital
-
Seoul、韓国、03080
- 募集
- Samsung Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Able to understand and give written informed consent.
-
Assigned female or male at birth, 18 years of age or older, and meet the age of majority/adulthood per local regulations.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
-
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria by investigator assessment.
-
Organ function requirements:
- Adequate hematologic function
- Adequate hepatic function
- Creatinine clearance
- Coagulation
-
Tissue requirement:
-
Parts A, B, C, and D:
- Pre-treatment tumor tissue is required.
-
Parts A and C backfill biopsy cohorts:
- Individuals must agree to fresh pre- and on-treatment biopsies.
-
-
Individuals assigned male at birth and individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception
-
Willing and able to comply with the requirements and restrictions in this protocol
-
Part A (GS-0201 Monotherapy Dose Escalation) Inclusion Criteria:
- Histologically/cytologically confirmed progressive/advanced solid tumors with selected molecular lesions.
- Individuals must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy
-
Part B (Dose Expansion) Inclusion Criteria:
-
Disease documented as:
-
Cohort B1:
- Histologically or cytologically confirmed progressive/advanced selected solid tumor diagnoses harboring defined molecular lesions
- Participants may potentially be required to forgo treatment with approved agent(s) to be able to participate in the study
-
Cohort B2:
- Histologically or cytologically confirmed progressive/advanced solid tumor diagnoses harboring defined molecular lesions not included in Cohort B1
-
-
Part C (Dose Escalation) Inclusion Criteria:
- Histologically or cytologically confirmed unresectable locally advanced/metastatic selected solid tumors
-
Part D (Dose Expansion) Inclusion Criteria:
-
Disease documented as:
-
Cohort D1:
- Histologically or cytologically confirmed unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)
-
Cohort D2:
- Recurrent/persistent endometrial cancer
-
Exclusion Criteria:
-
Pregnant or lactating females
-
Known hypersensitivity to any of the study drugs, its metabolites, or formulation excipients
-
Requirement for ongoing therapy with or use of any prohibited medications described in the protocol
-
Individuals with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with findings suggestive of MDS/AML
-
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of GS-0201
-
The therapies listed below within the specified timeframe:
- Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, biopsy) < 4 weeks prior to planned Cycle 1 Day 1
- Immunotherapy or biologic therapy < 21 days prior to planned Cycle 1 Day 1
- Chemotherapy < 14 days prior to planned Cycle 1 Day 1, or < 42 days for mitomycin or nitrosoureas
- Targeted small molecule therapy < 14 days prior to planned Cycle 1 Day 1
- Receipt of experimental therapy within 21 days or 5 experimental treatment half-lives (whichever is longer) prior to planned Cycle 1 Day 1
- Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started < 14 days prior to planned Cycle 1 Day 1 are not permitted. Hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started ≥ 14 days prior to planned Cycle 1 Day 1
- Radiotherapy within 2 weeks prior to planned Cycle 1 Day 1 and the radiation is not administered to a target lesion
- Any prior allogeneic tissue/solid organ transplantation, including allogeneic hematopoietic stem cell transplantation. Individuals with a history of autologous hematopoietic stem cell transplantation are also excluded
-
Have not recovered (ie, Grade 1 or lower) from AEs due to a previously administered agent
-
Prior treatment with approved or experimental prohibited agents as detailed in the protocol.
-
Diagnosis of immunodeficiency, either primary or acquired, or requires systemic corticosteroids (> 10 mg of prednisone daily, or equivalent). However, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted
-
Have an active second malignancy
-
Have known active central nervous system (CNS) metastases
-
Individuals with carcinomatous meningitis or primary CNS tumors are excluded regardless of clinical stability
-
Meet any of the following criteria for cardiac disease:
- Myocardial infarction or unstable angina pectoris within 6 months of enrollment
- History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication)
- QT interval > 470 msec
- New York Heart Association Class III or greater congestive heart failure or known left ventricular ejection fraction less than 40%
-
Meet any of the following infectious criteria:
- Have active serious infection requiring antimicrobials
- Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. In individuals with a history of HBV or HCV, individuals with detectable viral loads will be excluded
- Individuals who test positive for hepatitis B surface antigen. Individuals who test positive for hepatitis B core antibody are eligible with a negative HBV DNA by quantitative Polymerase chain reaction (PCR)
- Individuals who test positive for HCV antibody. Individuals who test positive for HCV antibody are eligible with a negative HCV RNA by quantitative PCR
- Individuals who test positive for HIV antibody
-
History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or radiation pneumonitis requiring steroids
-
Symptomatic ascites or pleural effusion
-
Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
-
Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the individuals participation in the study
-
Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of study drug(s) (inactivated, viral vector vaccines, and messenger RNA (mRNA) vaccines are allowed; seasonal vaccines should be up to date prior to planned Cycle 1 Day 1)
-
Parts C (Dose Escalation) and D (Dose Expansion): Combination Cohorts:
- Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal perforation within 6 months prior to planned Cycle 1 Day 1
- Individuals who previously received topoisomerase 1 inhibitors or antibody-drug conjugates containing a topoisomerase 1 inhibitor
- Known severe intolerance or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous (IV) immunoglobulin preparations; any history of anaphylaxis; history of human anti-human antibody response
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part A: GS-0201 Monotherapy Dose Escalation
Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first. |
Pill administered orally |
|
実験的:Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion
Participants with selected breast cancer indication will receive GS-0201 monotherapy at the recommended dose for expansion. |
Pill administered orally |
|
実験的:Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion
Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion. |
Pill administered orally |
|
実験的:Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)
Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first. |
Pill administered orally Administered intravenously
他の名前:
|
|
実験的:Part D: Cohort D1: Dose Expansion: GS-0201 + SG
Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG. |
Pill administered orally Administered intravenously
他の名前:
|
|
実験的:Part D: Cohort D2: Dose Expansion: GS-0201 + SG
Participants with recurrent/persistent endometrial cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG. |
Pill administered orally Administered intravenously
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
有害事象 (AE) および重篤な有害事象 (SAE) を経験した参加者の割合
時間枠:初回接種は最後の接種後30日以内(最長約109週間)。
|
初回接種は最後の接種後30日以内(最長約109週間)。
|
|
|
検査異常の発生率
時間枠:初回接種は最後の接種後30日以内(最長約109週間)。
|
初回接種は最後の接種後30日以内(最長約109週間)。
|
|
|
The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation
時間枠:First dose up to 30 days post last dose (Up to approximately 109 weeks).
|
DLTs are defined as any of the following treatment-emergent adverse events (AEs) regardless of attribution (graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0), unless clearly related to an underlying disease or extraneous causes, with onset within the DLT-evaluation period for the corresponding dose. |
First dose up to 30 days post last dose (Up to approximately 109 weeks).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
GS-0201 血漿濃度
時間枠:投与前および投与後から治療終了まで(最長105週間)
|
投与前および投与後から治療終了まで(最長105週間)
|
|
|
サシツズマブ ゴビテカン (SG) 血清濃度 (パート C および D のみ)
時間枠:投与前および投与後から治療終了まで(最長105週間)
|
投与前および投与後から治療終了まで(最長105週間)
|
|
|
Pharmacokinetic (PK) Parameter: Area Under the Concentration (AUC)0-24 of GS-0201
時間枠:Predose and postdose up to end of treatment (up to 105 weeks)
|
AUC0-24 is defined as the concentration of drug over time between time 0 and time 24 hours. |
Predose and postdose up to end of treatment (up to 105 weeks)
|
|
PK Parameter: Cmax of GS-0201
時間枠:Predose and postdose up to end of treatment (up to 105 weeks)
|
Cmax is defined as the maximum observed drug concentration. |
Predose and postdose up to end of treatment (up to 105 weeks)
|
|
PK Parameter: Tmax of GS-0201
時間枠:Predose and postdose up to end of treatment (up to 105 weeks)
|
Tmax is defined as the time to maximum observed concentration. |
Predose and postdose up to end of treatment (up to 105 weeks)
|
|
PK Parameter: AUC0-168 of SG (Parts C and D only)
時間枠:Predose and postdose up to end of treatment (up to 105 weeks)
|
AUC0-168 is defined as the concentration of drug over time between time 0 and time 168 hours. |
Predose and postdose up to end of treatment (up to 105 weeks)
|
|
PK Parameter: Cmax of SG (Parts C and D only)
時間枠:Predose and postdose up to end of treatment (up to 105 weeks)
|
Cmax is defined as the maximum observed drug concentration. |
Predose and postdose up to end of treatment (up to 105 weeks)
|
|
PK Parameter: Tmax of SG (Parts C and D only)
時間枠:Predose and postdose up to end of treatment (up to 105 weeks)
|
Tmax is defined as the time to maximum observed concentration. |
Predose and postdose up to end of treatment (up to 105 weeks)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Gilead Study Director、Gilead Sciences
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- GS-US-686-6854
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。